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Objectives We designed a prospective evaluation of the interaction between B-type natriuretic peptide (BNP) and the effect of
ranolazine in patients with acute coronary syndromes (ACS) as part of a randomized, blinded, placebo-controlled trial.
Background Ranolazine is believed to exert anti-ischemic effects by reducing myocardial sodium and calcium overload and
consequently ventricular wall stress. BNP increases in response to increased wall stress and is a strong risk indi-
cator in ACS.
Methods We measured plasma BNP in all available baseline samples (n  4,543) among patients with non–ST-segment
elevation ACS randomized to ranolazine or placebo in the MERLIN–TIMI 36 (Metabolic Efficiency With Ranolazine
for Less Ischemia in Non–ST Elevation Acute Coronary–Thrombolysis In Myocardial Infarction 36) trial and fol-
lowed them for a mean of 343 days. The primary end point was a composite of cardiovascular death, myocar-
dial infarction, and recurrent ischemia. BNP elevation was defined as 80 pg/ml.
Results Patients with elevated BNP (n  1,935) were at significantly higher risk of the primary trial end point (26.4% vs.
20.4%, p  0.0001), cardiovascular death (8.0% vs. 2.1%, p  0.001), and myocardial infarction (10.6% vs.
5.8%, p  0.001) at 1 year. In patients with BNP 80 pg/ml, ranolazine reduced the primary end point (hazard
ratio [HR]: 0.79; 95% confidence interval [CI]: 0.66 to 0.94, p  0.009). The effect of ranolazine in patients with
BNP 80 pg/ml was directionally similar for recurrent ischemia (HR: 0.78; 95% CI: 0.62 to 0.98; p  0.04) and
cardiovascular death or myocardial infarction (HR: 0.83; 95% CI: 0.66 to 1.05, p  0.12). There was no detect-
able effect in those with low BNP (p interaction value  0.05).
Conclusions Our findings indicate that ranolazine may have enhanced efficacy in high-risk patients with ACS identified by in-
creased BNP. The interaction of biomarkers of hemodynamic stress and the effects of ranolazine warrants additional
investigation. (Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST Elevation Acute Coronary Syn-
dromes; NCT00099788) (J Am Coll Cardiol 2010;55:1189–96) © 2010 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.09.068(
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ccepted September 21, 2009.ACS), are strongly associated with an increased risk of
ecurrent cardiovascular (CV) events (1–5). Notably, increases
n BNP and the N-terminal portion of BNP prohormone
dentify patients with ACS without systolic dysfunction or
igns of heart failure who are at higher risk of death and heart
See page 1197
ailure and provide prognostic information that is complemen-
ary to clinical risk predictors and other biomarkers including
ardiac troponin (1–3). Given this risk relationship, there
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BNP and the Effect of Ranolazine in ACS March 23, 2010:1189–96is intense interest in identifying
treatments that might modify the
risk associated with elevated con-
centrations of natriuretic peptides
in patients with ACS (6,7).
Ranolazine is an antianginal
that exerts anti-ischemic effects
without a clinically significant ef-
fect on heart rate or blood pres-
sure. At clinically relevant concen-
trations, ranolazine is an inhibitor
of the late phase of the cardiac
sodium current that is increased in
yocardial ischemia and contributes to detrimental myocardial
ellular sodium and calcium overload (8). In particular, disrup-
ion of sodium and calcium homeostasis can increase left
entricular diastolic tension and myocardial oxygen consump-
ion (9,10). In animal models of ischemia/reperfusion, ranola-
ine ameliorates these adverse consequences, preserving tissue
evels of adenosine triphosphate and improving myocardial
ontractile function (11). These findings suggested the
ypothesis that ranolazine might mitigate the substantially
igher risk of CV death and heart failure associated with
levated concentrations of BNP in ACS.
Therefore, we investigated the relationship between BNP
nd CV outcomes and the effect of ranolazine on that
elationship as a prespecified exploratory analysis included
n the design of the multinational, randomized, placebo-
ontrolled MERLIN–TIMI 36 (Metabolic Efficiency With
anolazine for Less Ischemia in Non–ST Elevation Acute
oronary Syndrome–Thrombolysis In Myocardial Infarc-
ion 36) trial (12).
ethods
atient population. The design and primary results of the
ERLIN–TIMI 36 trial were published previously
12,13). Eligible patients had at least 10 min of ischemic
ymptoms at rest and presented with one of the following:
levated biomarkers of myonecrosis, ST-segment depres-
ion 0.1 mV, a history of diabetes mellitus, or an inter-
ediate to high (3) TIMI risk score. Exclusion criteria
ncluded persistent ST-segment elevation, end-stage renal
isease requiring dialysis, cardiogenic shock, or a life ex-
ectancy 12 months. The protocol was approved by the
elevant institutional review boards, and written consent was
btained from all patients.
tudy treatment. Patients were randomized in a 1:1 ratio
o receive ranolazine or matching placebo. After 12 to 96 h
f an intravenous formulation, study medication (ranolazine
xtended release or placebo) was to be continued orally at a
ose of 1,000 mg twice daily until the end of the study.
ndividuals with renal insufficiency (estimated creatinine
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
cECG  continuous
electrocardiography
CI  confidence interval
CV  cardiovascular
HR  hazard ratio
MI  myocardial infarction
RR  relative risklearance 30 ml/h) received 500 mg twice daily. Individ- tals received standard medical and interventional therapy as
ictated by local practice guidelines. Randomization was
tratified by the intention for early invasive management.
NP testing. The protocol specified that blood samples be
btained at enrollment, on day 14, and at the final visit in
thylenediamine tetraacetic acid–anticoagulated plastic
ubes and plasma isolated within 60 min of sample acqui-
ition. Plasma samples were stored in plastic cryovials at
20°C or colder at the enrolling site until shipped to the
IMI Biomarker Core Laboratory (Boston, Massachusetts)
here they were maintained at 80°C or colder. BNP was
easured using the ADVIA Centaur (Siemens Healthcare
iagnostics, Inc., Deerfield, Illinois) (14) at the first thaw.
he decision limit of 80 pg/ml was previously established as
cut point for risk stratification in ACS (1,2) and validated
n multiple studies (7) including in our previous work with
his particular assay (15). Levels of cardiac troponin I were
easured using the TnI-Ultra assay (Siemens Healthcare
iagnostics, Inc.). The 99th percentile decision limit (0.04
g/ml, 10% coefficient of variation) was used for all
nalyses consistent with current guidelines (16). All biomar-
er testing was performed in the TIMI Biomarker Core
aboratory by personnel blinded to clinical outcomes and
reatment allocation.
nd points. The primary efficacy end point of the trial was
he composite of CV death, myocardial infarction (MI), and
ecurrent ischemia as defined previously (13). All compo-
ents of the primary efficacy end point, as well as symptom-
tic documented arrhythmia, and new or worsening heart
ailure were adjudicated by a blinded clinical events com-
ittee. New or worsening heart failure was defined as
ehospitalization or prolongation of the index hospitaliza-
ion (24 h) in an acute care facility primarily for the
reatment of heart failure along with an objective sign of
eart failure (13). Exercise tolerance test results were inter-
reted by a core laboratory (St. Louis University Core
lectrocardiographic Laboratory, St. Louis, Missouri) and
ontinuous electrocardiographic recordings were evaluated
n the TIMI Core Laboratory by reviewers blinded to
reatment and outcome. Ischemia on continuous electrocar-
iography (cECG) was defined as 1 mm ST-segment
epression lasting at least 1 min. Clinically significant
rrhythmias were defined as ventricular tachycardia of at
east 100 beats/min for 3 beats, supraventricular tachycar-
ia of at least 120 beats/min for 4 beats, bradycardia of
40 beats/min, pauses of 2.5 s, or third-degree heart
lock (13). Ventricular tachycardias were further catego-
ized according to number of beats (at least 4 beats, at least
beats) and duration 30 s (nonsustained) and 30 s
sustained) (17).
tatistical analysis. Plasma concentrations of BNP are
eported using the median and interquartile range of values.
he baseline characteristics of patients with and without
levated levels of BNP were compared using the Wilcoxon
ank sum test for continuous variables and the chi-square
est for categorical variables. The associations between BNP
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March 23, 2010:1189–96 BNP and the Effect of Ranolazine in ACSnd clinical outcomes were evaluated using the log rank test,
tratified by intention for early invasive management. Haz-
rd ratios (HRs) and the corresponding 95% confidence
ntervals (CIs) were estimated using a Cox proportional
azards regression model. Event rates are presented as
aplan-Meier failure rates at 30 days and 12 months. The
ncidence of arrhythmias on cECG was evaluated using a
ochran-Mantel-Haenszel test. Commensurate with the
rimary statistical plan for the trial, all analyses of the effect
f ranolazine were conducted stratifying by the intention to
se an early invasive strategy before randomization. Testing
or heterogeneity in the effect of ranolazine between patients
ith and without elevated levels of BNP was performed
sing Cox regression with terms for the main effects and for
he interaction of BNP status with treatment allocation.
his interaction was also assessed with adjustment for the
ffects of age, sex, diabetes, estimated creatinine clearance,
ody mass index, ST-segment depression on the presenting
lectrocardiogram, history of congestive heart failure,
vidence of heart failure at presentation, and baseline
ardiac troponin I result. In an exploratory analysis to
ssess the relative strength of the interaction with BNP,
e also tested for heterogeneity of the effect of ranolazine
ith other plausible potential predictors of benefit: age, sex,
iabetes, history of angina, index diagnosis, and ST-
egment depression.
Analyses were performed using STATA version 9.2
StataCorp., College Station, Texas). The p values (2-
ailed) 0.05 were considered to indicate statistical
ignificance.
Baseline Characteristics of Patients Stratified bTable 1 Baseline Characteristics of Patients
Characteristics
Age, yrs
Age 75 yrs
Female sex
White race
Weight, kg
Risk factors for atherosclerosis
Diabetes mellitus
Hypertension
Hyperlipidemia
Current smoker
Cardiac history
Previous MI
Previous coronary revascularization
Previous heart failure
Estimated creatinine clearance 60 ml/min*
Presenting syndrome
Time from symptoms, h
Non–ST-segment elevation MI
ECG: ST-segment depression 0.1 mV
TIMI risk score 4Data are expressed as median (25th, 75th percentile) or n/total (%). *Estima
BNP  B-type natriuretic peptide; ECG  electrocardiogram; MI  myocardesults
total of 4,543 samples were available for determination of
NP concentration at enrollment occurring at a median
25th, 75th percentile) of 23 h (13 h, 33 h) from symptom
nset. The median (25th, 75th percentile) concentration of
NP was 65 pg/ml (26, 147 pg/ml, respectively). The
lasma concentration of BNP exceeded 80 pg/ml in 1,935
42.6%) patients. The distribution of baseline BNP values
as well balanced between treatment groups: 65 pg/ml (26,
48 pg/ml, respectively) for the placebo group and 65 pg/ml
27, 146 pg/ml, respectively) for the ranolazine group.
atients with an elevated concentration of BNP (80
g/ml) had multiple other indicators of high risk. They were
lder, more often female, and more likely to have a history
f MI, heart failure, or diabetes (Table 1). At presentation,
atients with elevated BNP more frequently had ST-
egment depression, renal insufficiency, and a diagnosis of
I. Among those patients who underwent coronary an-
iography (n  2,536), patients with elevated BNP were
ore likely to have multivessel (2) coronary artery disease
68% vs. 54%, p  0.001), and disease involving the left
nterior descending artery (74% vs. 64%, p  0.001).
mong patients with an assessment of left ventricular
jection fraction obtained as part of clinical care (n 
,031), left ventricular ejection fraction was more commonly
ecreased (40%) in those patients with elevated BNP
21.5% vs. 7.1%, p  0.001). Baseline characteristics of
atients were well balanced between the placebo and rano-
azine groups among patients with BNP results from base-
ine (Online Table 1).
Ptified by BNP
80 pg/ml
1,935)
BNP <80 pg/ml
(n  2,608) p Value
60, 75) 60 (53, 68) 0.001
1,935 (26) 247/2,608 (9) 0.001
1,935 (39) 844/2,608 (32) 0.001
1,935 (97) 2,508/2,608 (96) 0.034
70, 89.5) 83 (74, 94.7) 0.001
1,935 (34) 8,17/2,608 (31) 0.044
1,927 (76) 1,896/2,591 (73) 0.030
1,757 (64) 1,662/2,369 (70) 0.001
1,934 (22) 723/2,607 (28) 0.001
1,910 (39) 859/2,588 (33) 0.001
1,933 (27) 695/2,606 (27) 0.98
1,935 (23) 486/2,608 (19) 0.001
1,925 (30) 337/2,602 (13) 0.001
4, 34) 22 (12, 33) 0.001
1,894 (64) 1,002/2,533 (40) 0.001
1,935 (46) 723/2,608 (28) 0.001
1,935 (58) 1,018/2,608 (39) 0.001y BNStra
BNP >
(n 
68 (
508/
747/
1,883/
80 (
661/
1,465/
1,129/
417/
749/
516/
449/
575/
24 (1
1,208/
894/
1,128/ted using the Cockroft-Gault equation.
ial infarction; TIMI  Thrombolysis In Myocardial Infarction.
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BNP and the Effect of Ranolazine in ACS March 23, 2010:1189–96NP and clinical outcomes. An elevated BNP concentra-
ion at enrollment identified a high-risk cohort of patients.
atients with baseline levels of BNP 80 pg/ml were at
ignificantly higher risk of CV death, MI, or recurrent
schemia at 30 days (p 0.0001) (Fig. 1) and at 1 year (p
.0001) (Fig. 2A). Patients with an elevated concentration
f BNP at baseline were also more likely to have ischemia
etected on continuous electrocardiographic monitoring
uring the first 7 days (26.8% vs. 17.3%, p  0.001) and
ere at a higher risk of CV death, MI, or heart failure
ndividually by 30 days and 1 year (p 0.001 for each) (Fig. 1).
In addition, we found that an elevated BNP concentra-
ion was associated with a higher risk of the broad pre-
efined composite arrhythmia end point (82% vs. 76%, p 
.001) as well as a higher risk of ventricular tachycardia 8
eats (7.2% vs. 5.7%, p  0.037), sustained ventricular
achycardia (0.75% vs. 0.24%, p  0.013), supraventricular
achycardia (57% vs. 46%, p  0.001), and atrial fibrillation
3.5% vs. 1.1%, p  0.001). In addition to having a higher
ncidence of arrhythmias detected on cECG, patients with
levated BNP were also at higher risk of sudden cardiac
eath at 1 year (3.0% vs. 0.9%, p  0.001). Patients with
levated BNP also had worse exercise performance (490 
50 s vs. 572  266 s on treadmill testing, p  0.001).
ffect of treatment with ranolazine. In the overall trial,
he primary end point occurred in 21.8% of patients in the
anolazine group and 23.5% of patients in the placebo group
y 1 year (p  0.11), with a 13% reduction in recurrent
schemia favoring treatment with ranolazine (HR: 0.87;
5% CI: 0.76 to 0.99; p  0.03) but no significant effect on
he incidence CV death or MI (p  0.87) (16). In this
nalysis based on BNP, ranolazine significantly reduced the
rimary end point (Fig. 2B) (HR: 0.79; 95% CI: 0.66 to
.94) among the high-risk cohort of patients with BNP
80 pg/ml, in contrast to a lack of detectable effect of
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March 23, 2010:1189–96 BNP and the Effect of Ranolazine in ACSoint (Fig. 3). Specifically, there was a similar but nonsig-
ificant pattern of reduction in the end points of recurrent
schemia (HR: 0.78; 95% CI: 0.62 to 0.98; p interaction 
.28) and CV death or MI (HR: 0.83, 95% CI: 0.66 to 1.05;
interaction  0.067). There was, however, no detectable
ffect of ranolazine on the incidence of new or worsening
eart failure in those with elevated BNP (HR: 0.99; 95%
I: 0.7 to 1.37; p interaction  0.54).
In addition, the risk of arrhythmias on cECG in patients
ith elevated BNP was reduced with ranolazine (relative
isk [RR]: 0.90; 95% CI: 0.86 to 0.94; p  0.001, p
nteraction 0.94). This effect included a consistent pattern
f reductions across each type of arrhythmia, including
entricular tachycardia 8 beats (6.3% vs. 8.2%; RR: 0.78;
5% CI: 0.56 to 1.08; p  0.13, p interaction  0.33),
upraventricular tachycardia (53.3% vs. 61.0%; RR: 0.88;
5% CI: 0.81 to 0.95; p  0.001, p interaction  0.095),
nd atrial fibrillation (3.1% vs. 3.8%; RR: 0.82; 95% CI:
.51 to 1.34; p  0.41, p interaction  0.57) with
anolazine compared with placebo. Sudden cardiac death
as numerically lower in the ranolazine group (HR: 0.66;
5% CI: 0.39 to 1.10; p 0.11). There was no difference in
xercise performance with ranolazine versus placebo (487 
48 s vs. 492  252 s, p  0.59) in those with elevated
NP.
Analysis of the change in BNP concentration from
nrollment to 14 days and to the final visit (among survi-
ors) revealed no significant difference between the ranola-
ine and placebo groups. The median change in BNP
etween day 0 and day 14 was 2 pg/ml in the ranolazine
roup and 0 pg/ml in the placebo group (p  0.30). The
espective values at the final visit were 7 and 9 pg/ml (p 
.43). The results were similar when restricted to those
atients with an initially elevated BNP (p  0.51).
ultivariable assessment. To assess whether the observed
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Figure 3 Kaplan-Meier Estimated 1-Year Incidence of CV Events
Sudden cardiac death (SCD), myocardial infarction (MI), recurrent ischemia (RI),
and new or worsening heart failure (HF) with ranolazine compared with placebo
among patients with baseline BNP results 80 pg/ml. RRR  relative risk
reduction; other abbreviations as in Figures 1 and 2.enefit of ranolazine on the primary end point in patients tith elevated BNP can be explained by other characteristics,
e performed an adjusted analysis of the interaction be-
ween BNP and the randomized treatment. We found that
fter adjusting for age, sex, diabetes, history of angina,
stimated creatinine clearance, body mass index, index
iagnosis, ST-segment depression, and baseline cardiac
roponin I result, the interaction term for BNP remained
ignificant (p  0.041). Testing of interaction terms for
ach of the other covariates revealed no other clinical
haracteristic that exhibited a stronger interaction with
anolazine than did BNP (p  0.15 for all). Similarly, the
xtent of coronary artery disease among those who under-
ent coronary angiography for the index event (n  2,536)
as not significantly associated with the effect of ranolazine
p interaction  0.73).
iscussion
n this nested prospective study of BNP in 4,500 patients,
e found that, consistent with previous observations, pa-
ients who had an elevated BNP concentration at baseline
ere at substantially higher risk of adverse outcomes after
on–ST-segment elevation ACS, including CV death,
eart failure, recurrent ischemic events, tachyarrhythmias,
nd reduced exercise capacity. In this analysis of the inter-
ction between baseline BNP concentration and outcomes
ith ranolazine, we found that ranolazine had a benefit
mong those patients with elevated BNP at presentation,
ith a significant reduction in the primary end point of CV
eath, MI, or recurrent ischemia. In contrast, in patients
ithout elevated BNP, ranolazine had no effect on these
utcomes. Ranolazine did not reduce the concentration of
NP over time nor the clinical end point of new or
orsening heart failure. Nonetheless, BNP successfully
dentified patients at higher risk of recurrent myocardial
schemia that was ameliorated by ranolazine.
atriuretic peptides in patients with myocardial ischemia.
yocardial ischemia is an important indirect and, possibly,
irect stimulus for the synthesis and release of natriuretic
eptides (6,18). In addition to increasing in the setting of
pontaneous myocardial ischemia during ACS, the blood
oncentrations of BNP and the N-terminal portion of BNP
rohormone also increase during provoked ischemia such as
uring exercise in patients with coronary disease (19–21) as
ell as after balloon inflation in uncomplicated coronary
ngioplasty (22,23). Moreover, the magnitude of the in-
rease in BNP during stress testing is proportional to the
ize of the ischemic territory as assessed with nuclear
ingle-photon emission computed tomography (19,20). Na-
riuretic peptide concentrations in patients with ischemic
eart disease are also associated with the anatomic severity
f coronary artery disease, including the number of diseased
essels and involvement of the proximal left anterior de-
cending artery (2,24,25).
The adverse prognosis associated with increased concen-
rations of natriuretic peptides in patients with acute and
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BNP and the Effect of Ranolazine in ACS March 23, 2010:1189–96hronic ischemic heart disease has been well established
5,7,26). In addition, for the first time in patients with ACS,
e found that patients who present with an elevated BNP
oncentration are at higher risk of clinically relevant ar-
hythmias and have diminished exercise performance. These
atter findings are novel and highlight the broad range of
orbidity associated with elevated natriuretic peptide levels
mong patients with ACS, even when clinical heart failure
s not present. These findings across multiple studies have
upported selective use of natriuretic peptides for risk
tratification in patients presenting with ACS in whom
dditional prognostic information is desired (7). However,
urrent guidelines for the use of biomarkers in patients with
schemic heart disease have not recommended routine
easurement of natriuretic peptides because, to date, there
as been no clear evidence that the results will influence
reatment strategy (7). For these reasons, there has been
trong interest in identifying therapies that specifically
odify the risk associated with elevated concentrations of
atriuretic peptides in this setting. Studies of the potential
or revascularization to reduce the increased risk associated
ith elevated natriuretic peptides have produced mixed
ndings (2,27,28). Few studies have examined the impact of
harmacotherapy on outcomes in patients with ACS and
levated BNP (29).
anolazine and myocardial ischemia and function. Rano-
azine inhibits the late phase of the sodium current in
ardiac myocytes and has several actions that have raised
he hypothesis that it might improve outcomes associated
ith myocardial dysfunction in ischemia and heart failure
8,13,30). Ranolazine enhances left ventricular systolic
unction and reduces left ventricular end-diastolic pres-
ure in animal models of both heart failure and ischemia
11,31–34). We now report in this large prospective
nalysis nested in a randomized, placebo-controlled trial
hat the risk associated with elevated BNP was reduced
ith ranolazine. Interestingly, in this group of high-risk
atients, in contrast with the overall trial results in which
anolazine had a neutral effect on CV death or MI, the
attern of event reduction was consistent with respect to
V death, MI, and recurrent ischemia individually, a
nding that was statistically heterogeneous in those with
NP 80 pg/ml.
Although our hypothesis that ranolazine might offer a
articular benefit in patients with increased ventricular wall
tress as reflected in the concentration of BNP is supported
y our findings, the mechanism of this benefit is not clear.
e did not find evidence that the mechanism is related to
reduction in wall stress as a result of therapy in view of the
bsence of a detectable effect of ranolazine on BNP con-
entration over time and the lack of an effect on the end
oint of new or worsening heart failure in this study. An
lternative explanation is that BNP is an integrative marker
f the severity of coronary artery disease and the territory at
isk of ischemia and other structural heart disease. This
roposal is supported by our previous work (1,2,25) and that Af others (3), which have linked natriuretic peptides to
isease severity in patients with ischemic heart disease. As
uch, BNP may serve as a risk indicator that identifies ACS
atients at high risk of adverse outcomes who have a greater
robability of benefit from ranolazine with respect to
schemia, and perhaps arrhythmias, rather than necessarily
hrough a significant direct reduction in hemodynamic
tress.
tudy limitations. Although the result of prespecified
nalyses, these intriguing findings must be regarded as
nherently exploratory in the context of the overall trial’s
eutral primary result. Although the observation of a
enefit of ranolazine with respect to the primary end
oint in those patients with elevated BNP is supported by
esting for statistical heterogeneity (p  0.05), the
onclusiveness of the testing for heterogeneity should be
nterpreted in the context of multiple testing. It is
ossible that because the timing of BNP measurement
as necessarily left flexible in the context of this multi-
ational outcomes trial, a true effect of ranolazine on
NP was not detected because of confounding pre-
nalytical variation. For these reasons, additional inves-
igation is needed to corroborate the benefit of ranolazine
n patients with elevated BNP that we observed in our
tudy to determine potential optimal cut points of inter-
ction and to define the possible mechanisms of benefit of
anolazine in these high-risk patients with ischemic heart
isease. Specifically, the hypothesis that indicators of
emodynamic stress identify patients who may derive
reater benefit from ranolazine requires prospective
esting.
onclusions
atients with elevated natriuretic peptides at the time of
resentation with an ACS are at substantially higher risk of
oor outcomes. The results of this planned exploratory
nalysis suggest that ranolazine may reduce the risk associ-
ted with elevated BNP. The potential interaction between
iomarkers of hemodynamic stress and the effects of rano-
azine warrants additional study.
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